Diptheria and Tetanus
"The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Bexsero is the second vaccine approved"...
Diphtheria and Tetanus
Prior to administration of DT, health-care personnel should inform the parent or guardian of the patient the benefits and risks of immunization, and also inquire about the recent health status of the patient to be injected.
As part of the child's permanent immunization record, the date, lot number and manufacturer of the vaccine administered MUST be recorded.11,12,13
The health-care provider should inform the parent or guardian of the patient about the potential for adverse reactions that have been temporally associated with DT administration. The parent or guardian should be instructed to report any serious adverse reactions to their health-care provider.
IT IS EXTREMELY IMPORTANT WHEN THE CHILD RETURNS FOR THE NEXT DOSE IN THE SERIES,THAT THE PARENT OR GUARDIAN OF THE PATIENT SHOULD BE QUESTIONED CONCERNING OCCURRENCE OF ANY SYMPTOMS AND/OR SIGNS OF AN ADVERSE REACTION AFTER PREVIOUS DOSE (see CONTRAINDICATIONS; ADVERSE REACTIONS sections).
The health-care provider should inform the parent or guardian of the patient the importance of completing the immunization series.
The health-care provider should provide the Vaccine Information Materials (VIMs) which are required to be given with each immunization.
Last reviewed on RxList: 6/8/2006
This monograph has been modified to include the generic and brand name in many instances.
Additional Diphtheria and Tetanus Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.